Release Date: July 29, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- GE HealthCare Technologies Inc GEHC reported a strong performance in Q2 2026 with an 11% increase in orders and a record backlog growth of $2.6 billion year-over-year.
- The company launched several new AI-enabled products, strengthening its competitive position and contributing to revenue growth.
- GEHC's pharmaceutical diagnostics and advanced imaging solutions segments led revenue growth, with strong performance in contrast media and US radiopharmaceuticals.
- The company is seeing strong interest in its Photon Counting CT platform, Photonova Spectra, and expects to expand its opportunity in Europe with CE marking in the second half of 2026.
- GEHC maintained its full-year guidance, reflecting confidence in achieving 3% to 4% organic sales growth and 10 to 40 basis points adjusted EBIT margin expansion.
Negative Points
- Patient Care Solutions (PCS) performance remained challenged, with a 13.5% decline in organic revenue due to operational fulfillment challenges.
- The company faced inflationary pressures, particularly from memory chips, oil, and freight, impacting margins.
- Despite strong orders growth, the PCS segment's EBIT was negative, highlighting ongoing supply chain and manufacturing issues.
- GEHC's adjusted EBIT margin of 14.2% was down 40 basis points year-over-year, partly due to inflation and challenges in the PCS segment.
- The CFO transition was noted as abrupt, raising concerns about continuity in financial leadership during a critical growth phase.
Q & A Highlights
Q: Can you provide more color on what drove the strength in orders in Q2, and how sustainable is that growth given concerns around capital equipment demand in the US?
A: Peter Arduini, President and CEO, explained that the 11% orders growth was broad-based and consistent across segments like molecular imaging, ultrasound, MR, and CT. There were no significant one-time factors; rather, it was due to strong execution and enterprise accounts. The demand for imaging studies remains robust, and the company is well-positioned to continue this momentum into the second half of the year.
Q: Could you help bridge the second half implied acceleration on a comp-adjusted basis embedded in the guidance?
A: James Saccaro, CFO, noted that the robust orders performance sets up well for the second half. The company expects PCS stabilization and growth in radiopharmaceuticals to support this. Historically, more profit is generated in the second half, and they anticipate margin improvements due to price and cost actions implemented in Q2.
Q: Can you discuss the strong performance in pharmaceutical diagnostics and the outlook for Plakadoramp?
A: Peter Arduini highlighted strong growth in contrast media and radiopharmaceuticals, driven by increased adoption of disease-specific tracers. The Plakadoramp is on track, with a 40% increase in doses delivered. The company remains confident in achieving $500 million in annual revenues by 2028.
Q: Why did you choose not to raise the EPS guidance despite the tariff refund and lower taxes?
A: Peter Arduini explained that while they recognized $0.04 of adjusted EPS related to tariffs, they chose to maintain guidance due to ongoing cost uncertainties, such as oil and chips. The company believes it has the appropriate cushion to meet and potentially exceed expectations.
Q: What is the outlook for costs, particularly regarding memory and oil inflation, and how will you hedge against potential increases?
A: Peter Arduini stated that the company plans to offset cost increases through adequate pricing. New products are focused on cost efficiency, and price actions taken in the first half will continue to benefit the second half and into 2027. James Saccaro added that despite high inflation, the company expanded margins, excluding PCS, by around 100 basis points.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
